跳至主要内容
临床试验/NCT01358695
NCT01358695已完成2 期

Clinical Trial To Evaluate ANT-1207 In Subjects With Lateral Canthal Lines

Anterios Inc.6 个研究点 分布在 1 个国家目标入组 111 人开始时间: 2011年5月1日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
已完成
发起方
Anterios Inc.
入组人数
111
试验地点
6
主要终点
Efficacy will be assessed by Investigator's Global Assessment Score

研究概览

简要总结

The purpose of this study is to provide evidence of the safety, tolerance, and efficacy of ANT-1207 in the treatment of Crow's Feet.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
30 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •mild to moderate Crow's Feet wrinkles (IGA 2-3) at rest
  • •moderate to severe Crow's Feet (IGA 3-4) on contraction
  • •willingness to refrain from any product affecting skin remodeling
  • •female subjects must be not pregnant and non-lactating

排除标准

  • •history of peri-ocular surgery, brow lift or related procedures
  • •procedures affecting the lateral canthal region in the prior 12 months
  • •application of topical prescription medication to the treatment area
  • •female subjects who are pregnant or are nursing a child

研究组 & 干预措施

Dose 1

Experimental

Dose 1

干预措施: ANT-1207 (Biological)

Placebo Comparator

Placebo Comparator

干预措施: Botulinum Toxin Type A (Biological)

Placebo Comparator

Placebo Comparator

干预措施: ANT-1207 (Biological)

Dose 4

Experimental

Dose 4

干预措施: Botulinum Toxin Type A (Biological)

Dose 3

Experimental

Dose 3

干预措施: Botulinum Toxin Type A (Biological)

Dose 5

Experimental

Dose 5

干预措施: Botulinum Toxin Type A (Biological)

Dose 2

Experimental

Dose 2

干预措施: Botulinum Toxin, Type A (Biological)

Dose 5

Experimental

Dose 5

干预措施: Botulinum Toxin, Type A (Biological)

Dose 4

Experimental

Dose 4

干预措施: Botulinum Toxin, Type A (Biological)

Dose 3

Experimental

Dose 3

干预措施: Botulinum Toxin, Type A (Biological)

Dose 3

Experimental

Dose 3

干预措施: ANT-1207 (Biological)

Dose 2

Experimental

Dose 2

干预措施: Botulinum Toxin Type A (Biological)

Dose 2

Experimental

Dose 2

干预措施: ANT-1207 (Biological)

Dose 1

Experimental

Dose 1

干预措施: Botulinum Toxin Type A (Biological)

Dose 1

Experimental

Dose 1

干预措施: Botulinum Toxin, Type A (Biological)

结局指标

主要结局

Efficacy will be assessed by Investigator's Global Assessment Score

时间窗: 2 weeks

Wrinkle scale with definitions of severity

次要结局

  • Subject Self Assessment (SSA) scale(2 Weeks)
  • Investigator Global Assessment scale(Week 1, 2, 4, 8, 12)

研究者

发起方
Anterios Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验

Clinical Trial To Evaluate ANT-1207 In Subjects With... | 临床试验